Hudson Valley Investment Advisors Inc. ADV Sells 7,513 Shares of Danaher Corporation $DHR

Key Points

• Hudson Valley Investment Advisors Inc. ADV reduced its stake in Danaher Corporation by 16.2%, selling 7,513 shares during the second quarter, now holding 38,994 shares valued at $7,703,000.
• Danaher has received mostly positive ratings from analysts, with a consensus price target of $245.91 and 17 analysts rating the stock as a Buy.
• The company announced a quarterly dividend of $0.32 per share, reflecting an annualized yield of 0.6%, with a payout ratio of 27.23%.

Hudson Valley Investment Advisors Inc. ADV decreased its position in Danaher Corporation (NYSE:DHR - Free Report) by 16.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,994 shares of the conglomerate's stock after selling 7,513 shares during the quarter. Hudson Valley Investment Advisors Inc. ADV's holdings in Danaher were worth $7,703,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Hills Bank & Trust Co grew its holdings in shares of Danaher by 0.3% in the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock valued at $3,693,000 after buying an additional 53 shares during the period. Worth Financial Advisory Group LLC grew its stake in Danaher by 4.6% in the second quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate's stock valued at $236,000 after acquiring an additional 53 shares during the period. Sageworth Trust Co grew its stake in Danaher by 2.3% in the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after acquiring an additional 54 shares during the period. 1834 Investment Advisors Co. increased its holdings in shares of Danaher by 3.3% in the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock worth $342,000 after acquiring an additional 54 shares in the last quarter. Finally, Bruce G. Allen Investments LLC increased its holdings in shares of Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate's stock worth $92,000 after acquiring an additional 54 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on DHR shares. Evercore ISI decreased their price objective on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Danaher in a report on Saturday, September 27th. Barclays reiterated an "overweight" rating and issued a $225.00 price target (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Guggenheim reiterated a "buy" rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday, July 23rd. Finally, Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Seventeen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Danaher has an average rating of "Moderate Buy" and a consensus price target of $245.91.

Danaher Price Performance

NYSE DHR opened at $215.05 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.41. The company has a market capitalization of $153.98 billion, a PE ratio of 45.75, a price-to-earnings-growth ratio of 3.00 and a beta of 0.77. The firm's 50 day moving average is $200.19 and its 200-day moving average is $197.42.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period last year, the company earned $1.72 earnings per share. The firm's revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher's dividend payout ratio (DPR) is 27.23%.

Insider Activity

In other news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 11.10% of the stock is owned by company insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.